Engineering and characterization of a mouse/human chimeric anti-phencyclidine monoclonal antibody

International Immunopharmacology

Volumn 8, Issue 1, 2008, Pages 1-11

  Lacy, H Marie ^a   Gunnell, Melinda G ^a   Laurenzana, Elizabeth M ^a   Owens, S Michael ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Arylcyclohexylamines; Chimeric antibody; Phencyclidine; Substance abuse; Therapeutic antibody

Indexed keywords

CHIMERIC MONOCLONAL ANTIBODY; COMPLEMENTARY DNA; CYCLOHEXYLAMINE; ETICYCLIDINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2; MONOCLONAL ANTIBODY; PHENCYCLIDINE; TENOCYCLIDINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN ANTIBODY REACTION; ARTICLE; CANCER CELL CULTURE; CHIMERA; CONTROLLED STUDY; DRUG ABUSE; DRUG BINDING; DRUG DEPENDENCE; FEASIBILITY STUDY; GENE EXPRESSION; GENETIC ENGINEERING; HEAVY CHAIN; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOCHEMISTRY; IMMUNOGENICITY; ISOELECTRIC POINT; LIGHT CHAIN; MOLECULAR WEIGHT; MOUSE; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; HALLUCINOGENS; HUMANS; HYBRIDOMAS; MICE; MOLECULAR SEQUENCE DATA; PHENCYCLIDINE; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS;

EID: 36649019572     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2007.09.020     Document Type: Article

References (36)

1. Haney M., and Kosten T.R. Therapeutic vaccines for substance dependence. Expert Rev Vaccines 3 1 (2004) 11-18
2. Kosten T., and Owens S.M. Immunotherapy for the treatment of drug abuse. Pharmacol Ther 108 1 (2005) 76-85
3. Gentry W.B., Pitas G., Laurenzana E.M., Williams D.K., and Owens S.M. Anti-phencyclidine monoclonal antibody binding capacity is not the only determinant of effectiveness, disproving the concept that antibody capacity is easily surmounted. Drug Metab Dispos 34 6 (2006) 906-912
4. Clark M. Antibody humanization: a case of the 'Emperor's new clothes'?. Immunol Today 21 8 (2000) 397-402
5. Brekke O.H., and Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2 1 (2003) 52-62
6. Isaacs J.D. From bench to bedside: discovering rules for antibody design, and improving serotherapy with monoclonal antibodies. Rheumatology (Oxford) 40 7 (2001) 724-738
7. McClurkan M.B., Valentine J.L., Arnold L., and Owens S.M. Disposition of a monoclonal anti- phencyclidine Fab fragment of immunoglobulin G in rats. J Pharmacol Exp Ther 266 3 (1993) 1439-1445
8. Proksch J.W., Gentry W.B., and Owens S.M. Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. J Pharmacol Exp Ther 292 3 (2000) 831-837
9. Hardin J.S., Wessinger W.D., Wenger G.R., Proksch J.W., Laurenzana E.M., and Owens S.M. A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats. J Pharmacol Exp Ther 302 1 (2002) 119-126
10. Laurenzana E.M., Gunnell M.G., Gentry W.B., and Owens S.M. Treatment of adverse effects of excessive phencyclidine exposure in rats with a minimal dose of monoclonal antibody. J Pharmacol Exp Ther 306 3 (2003) 1092-1098
11. Proksch J.W., Gentry W.B., and Owens S.M. The effect of rate of drug administration on the extent and time course of phencyclidine distribution in rat brain, testis, and serum. Drug Metab Dispos 28 7 (2000) 742-747
12. Hardin J.S., Wessinger W.D., Proksch J.W., and Owens S.M. Pharmacodynamics of a monoclonal antiphencyclidine Fab with broad selectivity for phencyclidine-like drugs. J Pharmacol Exp Ther 285 3 (1998) 1113-1122
13. Coloma M.J., Hastings A., Wims L.A., and Morrison S.L. Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J Immunol Methods 152 1 (1992) 89-104
14. McLean G.R., Nakouzi A., Casadevall A., and Green N.S. Human and murine immunoglobulin expression vector cassettes. Mol Immunol 37 14 (2000) 837-845
15. Owens S.M., Zorbas M., Lattin D.L., Gunnell M., and Polk M. Antibodies against arylcyclohexylamines and their similarities in binding specificity with the phencyclidine receptor. J Pharmacol Exp Ther 246 2 (1988) 472-478
16. Endo Y., Miyai K., Hata N., and Iijima Y. Effect of pH on antigen binding by clonotypic antibodies with different isoelectric points. Biotechnol Appl Biochem 9 1 (1987) 74-81
17. ten Kate C.I., Fischman A.J., Rubin R.H., Fucello A.J., Riexinger D., Wilkinson R.A., et al. Effect of isoelectric point on biodistribution and inflammation: imaging with indium-111- labelled IgG. Eur J Nucl Med 17 6-8 (1990) 305-309
18. Byrnes-Blake K.A., Laurenzana E.M., Landes R.D., Gentry W.B., and Owens S.M. Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats. Eur J Pharmacol 521 1-3 (2005) 86-94
19. Zhu Z., Hattori K., Zhang H., Jimenez X., Ludwig D.L., Dias S., et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia 17 3 (2003) 604-611
20. Lim K., Owens S.M., Arnold L., Sacchettini J.C., and Linthicum D.S. Crystal structure of monoclonal 6B5 Fab complexed with phencyclidine. J Biol Chem 273 44 (1998) 28576-28582
21. Isaacs J.D. The antiglobulin response to therapeutic antibodies. Semin Immunol 2 6 (1990) 449-456
22. Foote J., and Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 224 2 (1992) 487-499
23. Harris W.J. Production of humanized monoclonal antibodies for in vivo imaging and therapy. Biochem Soc Trans 23 4 (1995) 1035-1038
24. Riechmann L., Clark M., Waldmann H., and Winter G. Reshaping human antibodies for therapy. Nature 332 6162 (1988) 323-327
25. Weinblatt M.E., Maddison P.J., Bulpitt K.J., Hazleman B.L., Urowitz M.B., Sturrock R.D., et al. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum 38 11 (1995) 1589-1594
26. Lockwood C.M., Thiru S., Isaacs J.D., Hale G., and Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 341 8861 (1993) 1620-1622
27. Isaacs J.D., Manna V.K., Rapson N., Bulpitt K.J., Hazleman B.L., Matteson E.L., et al. CAMPATH-1H in rheumatoid arthritis-an intravenous dose-ranging study. Br J Rheumatol 35 3 (1996) 231-240
28. Isaacs J.D., Watts R.A., Hazleman B.L., Hale G., Keogan M.T., Cobbold S.P., et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340 8822 (1992) 748-752
29. Kuus-Reichel K., Grauer L.S., Karavodin L.M., Knott C., Krusemeier M., and Kay N.E. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?. Clin Diagn Lab Immunol 1 4 (1994) 365-372
30. Bell S.J., and Kamm M.A. Review article: the clinical role of anti-TNFalpha antibody treatment in Crohn's disease. Aliment Pharmacol Ther 14 5 (2000) 501-514
31. Reichert J.M. Monoclonal antibodies in the clinic. Nat Biotechnol 19 9 (2001) 819-822
32. van Vugt M.J., Kleijmeer M.J., Keler T., Zeelenberg I., van Dijk M.A., Leusen J.H., et al. The FcgammaRIa (CD64) ligand binding chain triggers major histocompatibility complex class II antigen presentation independently of its associated FcR gamma-chain. Blood 94 2 (1999) 808-817
33. Fearon D.T. Non-structural determinants of immunogenicity and the B cell co-receptors, CD19, CD21, and CD22. Adv Exp Med Biol 452 (1998) 181-184
34. Clark M.R. IgG effector mechanisms. Chem Immunol 65 (1997) 88-110
35. Routledge E.G., Falconer M.E., Pope H., Lloyd I.S., and Waldmann H. The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. Transplantation 60 8 (1995) 847-853
36. Pandey J. Immunoglobulin GM and KM allotypes and vaccine immunity. Vaccine 19 6 (2000) 613-617